Arkolith/Insider Trading/IGC/Form 4

Prins Richard K

DirectorIGC Pharma, Inc. (IGC) · full profile →Form 4 · filed Mar 15, 2024
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
11
5 non-derivative · 6 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Mar 13, 2024Option exercise(M)100K—$01.2M
Mar 13, 2024Option exercise(M)43K—$01.2M
Mar 13, 2024Option exercise(M)29K—$01.2M
Mar 13, 2024Option exercise(M)100K—$01.0M
Mar 13, 2024Option exercise(M)58K—$01.1M

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Mar 13, 2024Option exercise(M)71K—$0214K
Mar 13, 2024Option exercise(M)100K—$0200K
Mar 13, 2024Option exercise(M)58K—$058K
Mar 13, 2024Option exercise(M)100K—$0100K
Mar 13, 2024Grant(A)210K—$0210K
Mar 13, 2024Grant(A)175K—$0175K

Transaction Codes

M
Option exercise / conversion
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001185185-24-000261) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML